Achieve Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies - Additional Information (Detail)

Commitments and Contingencies - Additional Information (Detail)	12 Months Ended				1 Months Ended				1 Months Ended			1 Months Ended	12 Months Ended		12 Months Ended
	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Feb. 28, 2015 Subsequent Event USD ($)	Feb. 28, 2015 Subsequent Event BMR-217TH Place LLC USD ($)	Dec. 31, 2014 Excess lease facility [Member] USD ($)	Dec. 31, 2013 Excess lease facility [Member] USD ($)	Dec. 31, 2014 Other Long Term Assets [Member] USD ($)	Feb. 28, 2015 Termination Fee [Member] Subsequent Event BMR-217TH Place LLC USD ($)	Feb. 28, 2015 Contingent Fee [Member] Subsequent Event BMR-217TH Place LLC USD ($)	Dec. 31, 2014 CANADA CAD	Dec. 31, 2009 Teva Pharmaceutical Industries Ltd. [Member] Collaboration arrangement [Member] USD ($)	Dec. 31, 2014 Teva Pharmaceutical Industries Ltd. [Member] Collaboration arrangement [Member] USD ($)	Dec. 31, 2013 Teva Pharmaceutical Industries Ltd. [Member] Collaboration arrangement [Member] USD ($)	Dec. 31, 2014 Isis Pharmaceuticals Inc. and University of British Columbia [Member] USD ($)	Dec. 31, 2014 Isis Pharmaceuticals Inc. and University of British Columbia [Member] Collaboration arrangement [Member] CAD	Dec. 31, 2014 Isis Pharmaceuticals, Inc. [Member] Collaboration arrangement [Member] USD ($)
Other Commitments [Line Items]
Collaboration agreement aggregate amount												$ 50,000,000
Gross Proceeds	22,372,000		53,777,000										10,000,000
Direct and indirect costs incurred													30,000,000	30,000,000
Milestone payments																1,600,000	7,750,000
Amount receivable by Isis from TEVA as a milestone payment																	20.00%
Achievement of developmental and commercial milestones	370,000,000											370,000,000
Percentage of un-spent portion to be paid																	30.00%
Obligation to pay patent costs and annual license maintenance fees																8,000
Milestone payment																100,000	800,000
Expiry period of agreement of patented license																	20 years
Range of each product line																	10 years
Milestone payment due															20,000,000		20,000,000
Period of milestone payment															21 days		21 days
Reserve for contingency of non payment of non-royalty milestone amount															20,000,000		20,000,000
Milestone payment made															10,000,000		10,000,000
Balance amount of milestone payment															10,000,000		10,000,000
Expiration of operating lease agreement	2015-09
Future minimum annual lease payments under the Vancouver lease				144,000							85,000,000
Expiration of non-cancellable operating lease agreement	2017
Cash security deposit								500,000
Standby letter of credit	300,000
Lease liability						194,000	3,906,000
Lease termination agreement, date of termination					Mar. 01, 2015
Lease termination agreement, fee payable									2,000,000	1,300,000
Aggregate amount of funding received					20,000,000
Letter of credit drawn to pay deferred state sales tax					100,000
Consolidated rent and facilities expense	2,800,000us-gaap_OperatingLeasesRentExpenseNet	2,800,000us-gaap_OperatingLeasesRentExpenseNet	2,700,000us-gaap_OperatingLeasesRentExpenseNet
Indemnification obligations	0
Expenses related to indemnification issues	$ 0ogxi_IndemnificationExpense